Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Last trade$7.81
Day change+$0.105 (+1.36%)
Day range$7.51 – $8.15
Volume1,988
Market cap$54M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$54.39M
Price / earnings
—
Price / book
0.8×
Price / sales
0.99×
EV / sales
-1.23×
EV / EBITDA
1.7×
Profitability
Earnings per share
-$1.63
Return on assets
-8.52%
Return on equity
-16.84%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.72×
Quick ratio
4.72×
Cash ratio
4.56×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$57.63M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for XLO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$9.98M
$18.69M
$12.65M
$13.69M
$19.07M
$8.08M
$2.93M
$1.72M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$9.98M
$18.69M
$12.65M
$13.69M
$19.07M
$8.08M
$2.93M
$1.72M
Selling, general and administrative
$6.93M
$7.62M
$6.93M
$7.4M
$6.67M
$7.12M
$8.52M
$6.52M
Research and development
$14.81M
$14.56M
$19.83M
$18.12M
$14.32M
$15.33M
$8.27M
$8.84M
Total operating expenses
$21.73M
$22.18M
$26.76M
$25.52M
$21M
$22.45M
$16.78M
$15.35M
Operating income
-$11.75M
-$3.49M
-$14.11M
-$11.84M
-$1.93M
-$14.37M
-$13.85M
-$13.63M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$5.95M
-$6.37M
-$9.53M
$10.36M
-$16.29M
-$15.84M
-$13.27M
-$13.09M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.95M
-$6.37M
-$9.53M
$10.36M
-$16.29M
-$15.84M
-$13.27M
-$13.09M
Net income attributable to common shareholders
-$5.95M
-$6.37M
-$9.53M
$10.36M
-$16.29M
-$15.84M
-$13.27M
-$13.09M
EBITDA
-$11.43M
-$3.16M
-$13.77M
-$11.51M
-$1.59M
-$13.99M
-$13.35M
-$13.25M
Basic earnings per share
-$0.30
-$0.33
-$0.58
$0.95
-$1.58
-$2.30
-$2.49
-$2.82
Diluted earnings per share
-$0.30
-$0.33
-$0.58
$0.95
-$1.58
-$2.30
-$2.49
-$2.82
Recent news
Company coverage with links to the original publishers.
Xilio Therapeutics granted stock options to new employees and newly appointed Chief Medical Officer Yariv Houvras, M.D., Ph.D. on October 1, 2026. The company granted 100,895 shares to two new employees and 105,000 shares to Dr. Houvras at an exercise price of $8.91 per share, with a standard vesting schedule of 25% after one year followed by 36 monthly installments.
Xilio Therapeutics granted non-qualified stock options to purchase 19,865 shares to two new employees at an exercise price of $8.88 per share on September 1, 2026. The options have a ten-year term with 25% vesting on the first anniversary and the remaining 75% vesting monthly over three years, subject to continued employment.
Xilio Therapeutics granted non-qualified stock options to purchase 3,257 shares to two new employees at an exercise price of $8.48 per share on April 1, 2026. The options have a ten-year term with a 25% vesting on the first anniversary and remaining 75% vesting monthly over three years, subject to continued employment.
Xilio Therapeutics announced the pricing of an underwritten offering of 74.78 million pre-funded warrants at $0.5349 per warrant, expected to raise approximately $40 million in gross proceeds. The financing was led by existing investor Coastlands Capital and included participation from Gilead Sciences, OrbiMed, and Perceptive Advisors. Proceeds will be used to advance product development and for general corporate purposes.
Xilio Therapeutics will present clinical and preclinical data on tumor-activated immuno-oncology therapies at the Society for Immunotherapy of Cancer's annual meeting in November 2025, highlighting research on vilastobart, efarindodekin alfa, and masked T cell engager programs.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.